Guidance and quality standards awaiting development | Guidance

Showing 311 to 320 of 410

Guidance and quality standards awaiting development
Title	Type
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]	Technology appraisal guidance
Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [GID-TA12040]	Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]	Technology appraisal guidance
Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]	Technology appraisal guidance
Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [GID-TA12039]	Technology appraisal guidance
Setrusumab for treating osteogenesis imperfecta [ID6730]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals	Quality standard